Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

3.5K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.5K
Pneumothorax-II01:27

Pneumothorax-II

545
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
545
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

3.1K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.1K
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

2.7K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
2.7K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

1.4K
The pathophysiology of pneumonia involves the following steps:
1.4K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.8K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Major form of NUP98/HOXC11 fusion in adult AML with t(11;12)(p15;q13) translocation exhibits aberrant trans-regulatory activity.

Leukemia·2003
Same author

[Fluoride-oxide glass for high efficiency upconversion from IR to green].

Guang pu xue yu guang pu fen xi = Guang pu·2003
Same author

[In situ IR study of the reaction behavior of clusters [VnCr3-n (mu 3-O) (mu-O2CCH3)6(THF)3]X[n = 0-3, X = Cl-, ClO4-, (VO5)0.5-] and [VnFe3-n(mu 3-O) (mu-O2CCH3)6(THF)3]X(n = 0-3, X = Cl-) in nitrogen atmosphere].

Guang pu xue yu guang pu fen xi = Guang pu·2003
Same author

[In situ IR study of the reaction behavior of transition metal oxides-propionic acid system, Fe2Cr(mu 3-O) (mu-O2CC2H5)6(H2O)3Cl.xH2O and Cr3 (mu 3-O) (mu-O2CC2H5)6(H2O)3NO3.xH2O].

Guang pu xue yu guang pu fen xi = Guang pu·2003
Same author

[Monte Carlo simulation of FCS in a laser gradient field].

Guang pu xue yu guang pu fen xi = Guang pu·2003
Same author

[A study on the concentration quenching of Tm3+ upconversion luminescence].

Guang pu xue yu guang pu fen xi = Guang pu·2003
Same journal

[Clinical analysis of ultrasound-guided percutaneous sclerotherapy combined with radiofrequency ablation in the treatment of intrahepatic biliary cystadenoma].

Zhonghua yi xue za zhi·2026
Same journal

[Metabolic profiles in umbilical cord blood associated with neonatal brain injury in selective fetal growth restriction].

Zhonghua yi xue za zhi·2026
Same journal

[Relationship between the consistency of auxiliary provocation tests with the supine roll test and treatment outcomes for horizontal semicircular canal benign paroxysmal positional vertigo].

Zhonghua yi xue za zhi·2026
Same journal

[Early-and mid-trimester glycolipid metabolism indicators for predicting adverse pregnancy outcomes in normoglycemic women].

Zhonghua yi xue za zhi·2026
Same journal

[Value of a deep learning-based visual model for predicting postoperative upper limb functional recovery after severe acute cervical spinal cord injury].

Zhonghua yi xue za zhi·2026
Same journal

[Eosinophils and futile recanalization after thrombectomy in acute large vessel occlusion stroke: the mediating effect of malignant brain edema].

Zhonghua yi xue za zhi·2026
See all related articles

Related Experiment Video

Updated: Nov 4, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.5K

[Interstitial lung disease revisited].

H D Jiang1, B Chen2

  • 1Department of Respiratory Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.

Zhonghua Yi Xue Za Zhi
|May 28, 2021
PubMed
Summary
This summary is machine-generated.

New insights into interstitial lung disease (ILD) improve classification and treatment. Anti-fibrotic drugs now treat progressive-fibrosing ILD, and hypersensitivity pneumonitis is categorized into fibrotic and nonfibrotic types.

More Related Videos

Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation
06:15

Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation

Published on: November 10, 2023

1.1K
A Standardized Method for Measuring Internal Lung Surface Area via Mouse Pneumonectomy and Prosthesis Implantation
08:46

A Standardized Method for Measuring Internal Lung Surface Area via Mouse Pneumonectomy and Prosthesis Implantation

Published on: July 26, 2017

13.6K

Related Experiment Videos

Last Updated: Nov 4, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.5K
Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation
06:15

Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation

Published on: November 10, 2023

1.1K
A Standardized Method for Measuring Internal Lung Surface Area via Mouse Pneumonectomy and Prosthesis Implantation
08:46

A Standardized Method for Measuring Internal Lung Surface Area via Mouse Pneumonectomy and Prosthesis Implantation

Published on: July 26, 2017

13.6K

Area of Science:

  • Pulmonology
  • Rheumatology
  • Radiology

Background:

  • Interstitial lung disease (ILD) encompasses over 200 heterogeneous subtypes, presenting diagnostic and therapeutic challenges.
  • Recent advancements offer new understanding in clinical classification, disease behavior, early diagnosis, and treatment of ILD.
  • Anti-fibrotic therapies have expanded from idiopathic pulmonary fibrosis (IPF) to progressive-fibrosing ILD (PF-ILD).

Purpose of the Study:

  • To review recent advancements in understanding and managing interstitial lung diseases.
  • To highlight the value of new classifications for treatment strategies.
  • To emphasize the importance of early diagnosis and longitudinal surveillance for specific ILD subtypes.

Main Methods:

  • Review of recent clinical practice guidelines and research.
  • Analysis of expanded therapeutic applications for anti-fibrotic drugs.
  • Categorization of hypersensitivity pneumonitis (HP) into distinct clinical phenotypes.

Main Results:

  • Clinical classification of ILD based on disease behavior and fibrotic phenotype is crucial for treatment strategies.
  • Hypersensitivity pneumonitis (HP) is now classified into nonfibrotic and fibrotic phenotypes.
  • Interstitial pulmonary abnormalities (ILA) may indicate subclinical ILD, necessitating long-term follow-up for early diagnosis.

Conclusions:

  • Revised ILD classification and expanded anti-fibrotic drug use enhance treatment for progressive forms.
  • Early detection of ILD through monitoring ILA and recognizing IPAF as a potential precursor to CTD is vital.
  • Longitudinal surveillance of IPAF patients is essential for monitoring evolution to connective tissue disease (CTD).